Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020

Jun 15, 2020 7:00am EDT

Baudax Bio Secures $50 Million Credit Facility

Jun 01, 2020 7:00am EDT

Baudax Bio Reports First Quarter 2020 Financial Results

May 08, 2020 7:00am EDT

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020

May 05, 2020 7:00am EDT

Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters

May 01, 2020 4:05pm EDT

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

Apr 23, 2020 7:00am EDT

Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain

Apr 07, 2020 8:00am EDT

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 03, 2020 6:40pm EDT

Baudax Bio Announces Closing of $25 Million Public Offering of Securities

Mar 26, 2020 11:35am EDT

Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants

Mar 24, 2020 9:15am EDT